

Contact Person: Jeffrey P. Koplan, M.D., Executive Secretary of Committee, Centers for Disease Control (1-2047) 1600 Clifton Road, NE., Atlanta, Georgia 30333, TELEPHONES: FTS: 236-3751, Commercial: 404/329-3751.

Purpose: The Committee is charged with advising on the appropriate uses of immunizing agents.

Agenda: The Committee will discuss several parts of the adult immunization statement; discuss formulation of statements on pneumococcal polysaccharide, influenza, rabies, and rubella vaccines; discuss screening of pregnant women for hepatitis B; and will consider other matters of relevance among the Committee's objectives.

Agenda items are subject to change as priorities dictate.

The meeting is open to the public for observation and participation. A roster of members and other relevant information regarding the meeting may be obtained from the contact person listed above.

Dated: March 13, 1984.

William C. Watson, Jr.,
Acting Director, CDC.

[FR Doc. 84-7463 Filed 3-19-84; 8:45 am]

BILLING CODE 4160-18-M

Food and Drug Administration

[Docket No. 82P-0252 and 82P-0353]

Availability of Approved Variances for Laser-Aimed Firearms

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that variances from certain requirements of the performance standard for laser products have been approved by FDA's National Center for Devices and Radiological Health for specified firearm laser aiming products manufactured by two organizations. The products are intended to be mounted onto a customer-supplied weapon and, as an alignment device, will aid in improving aiming speed and accuracy.

DATES: The effective dates and termination dates of the variances are listed in the table below under "Supplementary Information".

ADDRESS: The applications and all correspondence concerning the applications have been placed on display in the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Glenn E. Conklin, National Center for Devices and Radiological Health (HFZ-84), Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857, 301-443-4874.

SUPPLEMENTARY INFORMATION: Under the provisions of § 1010.4 (21 CFR 1010.4) of the regulations governing establishment of performance standards under section 358 of the Radiation Control for Health and Safety Act of 1968 (42 U.S.C. 263f), both of the organizations listed in the table below have been granted a variance from certain requirements of the performance standard for laser products § 1040.10 (21 CFR 1040.10). The products consist of a laser system built into a weapon to project an intense, collimated beam of red light downrange to align the weapon's point of aim with the intended target. Thus, the laser-aimed firearm is considered to be a surveying, leveling, and alignment laser product subject to all the applicable provisions of 21 CFR 1040.10 and 1040.11(b) including the power limit of 5 milliwatts.

The specific requirements of the standard for which the variances were granted pertain to the performance features of a remote control connector § 1040.10(f)(3), emission indicator § 1040.10(f)(5)(ii), or beam attenuator § 1040.10(f)(6). All other provisions of § 1040.10 remain applicable to the laser firearms.

Suitable means of radiation protection will be provided by conditions on the physical and optical design and on the labeling of the product. The laser system

incorporated into the lease-aimed firearm can be turned only by using a normally-off monetary switch; the actuation of this switch is significantly distinct but not necessarily physically separate from the trigger action of the weapon. In addition, labels and instructions provided to users of laser-aimed firearms, including servicing dealers and distributors, will include adequate information and instructions to assure that individuals who are untrained in the safe use of lasers can use the product safely.

The organizations granted the variances are to establish and maintain current records with respect to the radiation safety of the laser-aimed firearms, especially with regard to those sold to the general public. These records are to include copies of all written communications between the manufacturer and dealers, distributors, and purchasers concerning radiation safety, including complaints, investigations, instructions, or explanations affecting the use, repair, adjustment, maintenance, or testing of the listed product.

To associate the product with the variance granted to the manufacturer of that product, each product shall bear on the certification label required by § 1010.2(a) (21 CFR 1010.2(a)), the docket number (which is the identifying number of the variance and the effective date of the variance as specified in the table below.

Docket No. & organization granted the variance	Laser product	Paragraph in 21 CFR 1040.10 pertaining to variance	Effective date/termination date
82P-0252 Power Technology Inc., 7925 Mabelvale Cutoff Mabelvale, Arkansas 72103.	PTI laser pistol sight assembly and PTI laser rifle sight assembly.	(f)(3), (f)(5)(ii), (f)(6).....	Jan. 19, 1983- Jan. 19, 1984.
82P-0353 Laser Arms Corp. P.O. Box 4647 Las Vegas, Nevada 89127.	Laser gun-sight model R-100.....	(f)(5)(ii)	Feb. 4, 1983- Feb. 4, 1984.

In accordance with § 1040.4, the applications and all correspondence (including the written notice of approval) on the various applications have been placed on public display in the Dockets Management Branch (address above), and may be seen in that office between 9 a.m. and 4 p.m., Monday through Friday.

Dated: March 13, 1984.

William F. Randolph,
Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 84-7355 Filed 3-19-84; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 84N-0077]

Dental X-Ray Patient Selection Criteria Panel; Meeting

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing a

forthcoming meeting of the Dental X-Ray Patient Selection Criteria Panel. This is the second meeting of the Panel. The meeting is being called to continue the assessment of the existing state of knowledge regarding the use of dental radiography on the asymptomatic patient and to develop patient selection criteria for selected examinations.

DATES: Open sessions: April 4, 1984, 8:30 a.m. and 9 a.m. and April 5, 1984, 8:30 a.m. to 9 a.m.; closed sessions: April 4, 1984, 9:15 a.m. to 4:30 p.m. and April 5, 1984, 9:15 a.m. to 12 m.

ADDRESS: The Panel meeting will be held at the Twinbrook Bldg., Rm. T-400, 12720 Twinbrook Parkway, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Lireka P. Joseph, National Center for Devices and Radiological Health (HFZ-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-443-4600.

SUPPLEMENTARY INFORMATION: Through the National Center for Devices and Radiological Health (NCDRH), FDA conducts and supports research and training to minimize unproductive radiation exposure from diagnostic radiological examinations. One possible source of unproductive radiation exposure is radiological examinations that are not likely to affect patient management. To reduce the use of ineffective examinations, it is important that the dentist have current information about when a given radiological study is likely to provide needed diagnostic information. This information can take the form of decision guidelines based on patient signs, symptoms, or history, sometimes known as "patient selection criteria."

Under one part of a program designed to facilitate the development and testing by the dental profession of patient selection criteria for diagnostic radiological examinations, FDA is providing logistical support for the convening of a small panel of clinical and scientific experts to formulate draft patient selection criteria or statements of use. A detailed description of the X-ray patient selection criteria development process was published in the *Federal Register* of June 9, 1981 (46 FR 30568).

Any interested person who wishes to request time for oral presentations during the open portion of the meeting or who would like to submit written comments to the Panel and is unable to attend open portions of the meeting should inform the contact person listed above, either orally or in writing, by March 23, 1984. Persons attending the meeting who did not request time for an oral presentation will be permitted to make a presentation at the conclusion of the open portion if time permits.

A list of committee members, the meeting agenda, and the summary of the previous Panel meeting may be reviewed at the Dockets Management Branch (address above), between 9 a.m. and 4 p.m., Monday through Friday. The

summary of the Panel meeting contains minutes of the open session and copies of written data and views submitted to the Panel in open session.

Dated: March 13, 1984.

William F. Randolph,
*Acting Associate Commissioner for
Regulatory Affairs.*

[FR Doc. 84-7354 Filed 3-15-84; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 84F-0048]

The Dow Chemical Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that The Dow Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of hydroxypropyl methylcellulose in food with hydroxypropoxy and methoxy substitution ranges expanded from the ranges currently permitted.

FOR FURTHER INFORMATION CONTACT: James H. Maryanski, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5740.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 4A3768) has been filed by The Dow Chemical Co., Midland, MI 48640, proposing that § 172.874 *Hydroxypropyl methylcellulose* (21 CFR 172.874) be amended in paragraph (a) to provide for the safe use of the additive in food with hydroxypropoxy and methoxy substitution ranges expanded from the ranges currently permitted.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: March 7 1984.

Richard J. Ronk,
Acting Director, Bureau of Foods.

[FR Doc. 84-7361 Filed 3-19-84; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 84F-0050]

ICI Americas, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that ICI Americas, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of polysorbate 60 as an emulsifier in ice cream, frozen custard, ice milk, fruit sherbet, and nonstandardized frozen desserts.

FOR FURTHER INFORMATION CONTACT: Michael E. Kashtock, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 4A3774) has been filed by ICI Americas, Inc., Wilmington, DE 19897, proposing that the food additive regulations be amended to provide for the safe use of polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) as an emulsifier in ice cream, frozen custard, ice milk, fruit sherbet, and nonstandardized frozen desserts when used alone or in combination with polysorbate 65 and/or polysorbate 80.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: March 7, 1984.

Richard J. Ronk,
Acting Director, Bureau of Foods.

[FR Doc. 84-7362 Filed 3-19-84; 8:45 am]

BILLING CODE 4160-01-M

[Docket No. 84F-0054]

American Cyanamid Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that American Cyanamid Co. has filed a petition proposing that the food additive

regulations be amended to provide for the safe use of poly[(6-morpholino-8-triazine-2,4-diyl)[(2,2,6,6-tetramethyl-4-piperidyl)imino]hexamethylene[(2,2,6,6-tetramethyl-4-piperidyl)imino]hexamethylene[2,2,6,6-tetramethyl-4-piperidyl]imino]] as a light stabilizer for polyolefins.

FOR FURTHER INFORMATION CONTACT: Rudolph Harris, Bureau of Foods (HFF-334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-472-5690.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5), 72 Stat. 1786 (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 4B3780) has been filed by American Cyanamid Co., One Cyanamid Plaza, Wayne, NJ 07470, proposing that § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) be amended to provide for the safe use of poly[(6-morpholino-8-triazine-2,4-diyl)[(2,2,6,6-tetramethyl-4-piperidyl)imino]hexamethylene[(2,2,6,6-tetramethyl-4-piperidyl)imino]] as a light stabilizer for polyolefins.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the *Federal Register* in accordance with 21 CFR 25.40(c) (proposed December 11, 1979; 44 FR 71742).

Dated: March 7, 1984.

Richard J. Ronk,
Acting Director, Bureau of Foods.
[FR Doc. 84-7359 Filed 3-19-84; 8:45 am]
BILLING CODE 4160-01-M

[Docket Nos. 80P-0157 et al.]

Availability of Approved Variances for Laser Light Shows

AGENCY: Food and Drug Administration.
ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that variances from the performance standard for laser products have been approved by the National Center for Devices and Radiological Health (NCDRH) for 10 organizations that manufacture and produce laser light shows, or the laser light show projector, or both the light show and projector. The projector provides a laser light display to produce a variety of special lighting effects. The principal use of these products is to provide entertainment to general audiences.

DATES: The effective dates and termination dates of the variances are listed in the table below under "Supplementary Information."

ADDRESS: The applications and all correspondence on the various applications have been placed on display in the Dockets Management Branch (HFA-305), Food and Drug Administration, Rm. 4-62, 5600 Fishers Lane, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Glenn E. Conklin, National Center for

Devices and Radiological Health (HFZ-84), Food and Drug Administration, Rockville, MD 20857, 301-443-4874.

SUPPLEMENTARY INFORMATION: Under § 1010.4 (21 CFR 1010.4) of the regulations governing establishment of performance standards under section 358 of the Radiation Control for Health and Safety Act of 1968 (42 U.S.C. 263f), each of the 10 organizations listed in the table below has been granted a variance from § 1040.11(c) (21 CFR 1040.11(c)) of the performance standard for laser products.

Each variance permits the listed manufacturer to introduce into commerce a demonstration laser product which is the particular variety of laser light show, or laser light show projector, or both, assembled and produced by the manufacturer. Each of the shows has levels of accessible laser radiation in excess of Class II levels but not exceeding those required to perform the intended function of the product. Suitable means of radiation protection are provided by constraints on the physical and optical design, by warnings in the user manual and on the product, and by procedures for personnel who will operate the products. To associate the product with the variance granted to the manufacturer of that product, each product shall bear on the certification label required by § 1010.2(a) (21 CFR 1010.2(a)) the docket number (which is the identifying number of the variance) and effective date of the variance as specified in the table below. By letter to each manufacturer, the Deputy Director of NCDRH approved the requested variances.

Docket No.	Manufacturing organization	Demonstration laser products	Effective date and termination date
80P-0157 (Amendment)	Image Engineering Corp., 10 Beacon Street, Somerville, Mass. 02143.	Laser light show assembled and produced by Image Engineering Corp. for the Goodyear Exhibit at the Association of the U.S. Army trade show in Wash., D.C., from the 15th through the 19th of October 1983.	Oct. 14, 1983- Oct. 20, 1983.
81P-0264 (Extension)	Laser World, Inc., P.O. Box 8021, Maitland, Fla. 32751	Rainbow 3 AK projector	Sept. 9, 1983- Sept. 9, 1985.
81P-0389 (Amendment)	Mrs. Nancy Gorglione d.b.a. Laser Affiliates/L.A.S.E.R., 973 Page Street, San Francisco, Calif. 94117.	Laser light shows using Class II, III, and/or IV helium/neon, argon, helium-cadmium and/or krypton lasers.	June 16, 1983- Dec. 8, 1984.
83V-0151 (Amendment)	Precision Projection Systems, Inc., 11563 Radley Street, Artesia, Calif. 90701.	Laser light shows assembled and produced by Precision Projection Systems Inc., using certified Class IIIb or Class IV Laser Images CS Series or Mark IV Series laser projectors.	Oct. 24, 1983- Dec. 16, 1985.
83V-0204	Laser Optronics, P.O. Box 1776, 1044 North 800 East, Orem, Utah 84058.	Laser light shows assembled and produced by Laser Optronics using the Audio-Visual Imagineering AVI S400 laser projection system.	Sept. 27, 1983- Sept. 27, 1985.
83V-0209	Laser Light Entertainment Ltd., 3130 Ala Ilima St., No. 6A, Honolulu, Hawaii 96818.	Laser light shows using the Metatron Laser Arts Model ML 95-5K or the Laser Light Entertainment Model ML 600A.	Sept. 27, 1983- Sept. 27, 1985.
83V-0306	Williamette Science & Technology Center, 1331 West Broadway, Eugene, Oreg. 97402.	Williamette Science & Technology Center laser light show using argon & krypton ion lasers.	Sept. 26, 1983- Sept. 26, 1984.
83V-0307	Foursight Visual Systems, Inc., 37521 Larkin Ave., Palm-dale, Calif. 93550.	Foursight Visual Systems Model 118 laser projector and ion laser light shows assembled and produced by the firm. The projector may be sold or employed in the firm's laser light shows.	Sept. 15, 1983- Sept. 15, 1985.
83V-0322	Baumann LASCAN, Communication-Design, Sallerstr.—10, D-4000, Duesseldorf 11, West Germany.	Class IV Baumann LASCAN System—containerized laser projection system and laser light shows assembled and produced by Baumann LASCAN, Communication-Design.	Dec. 12, 1983- Dec. 12, 1985.
83V-0431	Laser Dynamics, Inc., 5020 S. Atlanta Rd., Suite 3, Atlanta, Ga. 30080.	Laser Media LMS 007 laser projector	Jan. 3, 1984- Jan. 3, 1986.

In accordance with § 1010.4, the applications and all correspondence (including the written notice of approval) on the various applications have been placed on public display under the designated docket number in the Dockets Management Branch (address above), and may be seen in that office between 9 a.m. and 4 p.m., Monday through Friday.